Intensive Short-Term Therapy Targets Beta-Cell Function in Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and beta-cell dysfunction, leading to chronic hyperglycemia. While standard treatments manage symptoms, they often do not fully address the underlying pathologies or prevent disease progression. This pilot study aimed to evaluate if an intensive, short-term, multi-drug de-escalation treatment (DET) could significantly impact beta-cell function and insulin resistance in T2DM patients.

As this was a pilot study with an unknown status, specific outcome data on beta-cell function and insulin resistance are not yet available from this registration. However, the intensive de-escalation treatment (DET) was designed with the hypothesis that it would achieve several key physiological improvements. It was anticipated that the combination therapy would lead to a significant reduction in glucose toxicity, thereby improving beta-cell function and enhancing insulin sensitivity. The inclusion of GLP-1 agonists (liraglutide, exenatide) aimed for weight loss and anti-inflammatory effects, while SGLT-2 inhibitors were expected to lower blood glucose by increasing glucose excretion. The use of insulin was intended to provide beta-cell rest, and pioglitazone aimed to enhance insulin sensitivity in peripheral tissues. The primary goal was to evaluate if this multi-drug approach could induce remission or significant improvement in Type 2 Diabetes Mellitus by addressing its underlying pathologies more effectively than standard treatment.